Security key
92765F108
Viracta Therapeutics, Inc. - Common Stock (VIRX)
CUSIP: 92765F108
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 5,587,200
- Total 13F value
- $1,291,746
- Share change
- -3,375,953
- SEC-reported price per share
- $0.23
- Number of holders
- 37
- Value change
- -$1,975,272
- Number of buys
- 15
- Number of sells
- 14
- Shares outstanding
- 19,711,628
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
37
Top holders
10
VIRX full security history
Ownership snapshot
Full 13F holder table
Viracta Therapeutics, Inc. SEC filings
Viracta Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of VIRX - Viracta Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
15/15
Latest evidence
30 Jun 2024
13F
Lead comparable stake: 18%
Showing 1-6 of 15 holder rows.
Quick read
BVF INC/IL leads the comparable SEC ownership view at 18%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BVF INC/IL's linked filing trail.
Comparable ownership
Top 5
BVF INC/IL
18%
CITADEL ADVISORS LLC
7.7%
VANGUARD GROUP INC
5.9%
Samsara BioCapital, LLC
3.5%
Laurion Capital Management LP
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BVF INC/IL |
13F
Company
|
18%
|
$1,965,292
3,614,662 shares
|
— | 30 Jun 2024 |
| CITADEL ADVISORS LLC |
13F
Company
|
7.7%
|
$826,554
1,520,240 shares
|
— | 30 Jun 2024 |
| VANGUARD GROUP INC |
13F
Company
|
5.9%
|
$631,388
1,161,280 shares
|
— | 30 Jun 2024 |
| Samsara BioCapital, LLC |
13F
Company
|
3.5%
|
$374,995
689,709 shares
|
— | 30 Jun 2024 |
| Laurion Capital Management LP |
13F
Company
|
2.1%
|
$221,448
407,299 shares
|
— | 30 Jun 2024 |
| Aisling Capital Management LP |
13F
Company
|
1.5%
|
$156,896
288,571 shares
|
— | 30 Jun 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
37
Shares
5,587,200
Rows available
37
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
35
Q3 2024 holders
37
Holder diff
2
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|